| TLRY Stock | | | CAD 9.48 -0.03 -0.32% |
Operating Profit Margin is evolving in a expanding direction across reporting periods.
This page complements
Tilray Technical models with financial statement trends. It adds volatility and performance context in a neutral, informational way.
Tilray Correlation provides competitor comparison context for Tilray. This supports competitive context.
Evaluating Tilray's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Tilray Inc's fundamental strength.
Below is the plot of the Operating Profit Margin of Tilray Inc over the last few years. It is Tilray's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tilray's overall financial position and show how it may be relating to other accounts over time.
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. TILRAY INC is traded on Toronto Stock Exchange in Canada. This stock section frames Tilray within its peer set and highlights how fundamentals align with price behavior. Current metrics include P/E of 8.23, P/B of 0.51, profit margin of -2.52%. Tilray has a market cap of 1.1 B, P/E of 8.23, ROE of -84.14%.
Methodology
Unless otherwise specified, financial data for Tilray Inc is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Tilray (CA:TLRY) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We reference public filings and market reference sources and regulatory disclosures, including those published by U.S. Securities and Exchange Commission (SEC) via EDGAR. Data may be normalized and delayed in some cases. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Tilray Inc may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial Board
and ratio context. Ratios and trend metrics help frame Tilray's operating context.
Tilray Correlation provides competitor comparison context for Tilray. This supports competitive context.
Analysis related to Tilray should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the
Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
The concept of value for Tilray differs from its quoted price, since each reflects a different lens. For Tilray, key inputs include a P/E ratio of 8.23, a P/B ratio of 0.51, a profit margin of -2.52%, and ROE of -84.14%. Market price reflects the current exchange level formed by active bids and offers.